Sutro Biopharma financials
$16.10+0.44%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.8M | $14.5M | $11.6M | $9.7M | $63.7M | $17.4M | $14.8M | $8.5M | $25.7M | $13.0M | $113.7M | $16.9M |
| Gross profit | $9.8M | $14.5M | $11.6M | $9.7M | $63.7M | $17.4M | $14.8M | $8.5M | $25.7M | $13.0M | $113.7M | $16.9M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$29.9M | -$29.7M | -$38.0M | -$48.5M | -$3.3M | -$68.5M | -$65.3M | -$67.9M | -$48.7M | -$56.6M | $43.2M | -$44.0M |
| Net income | -$38.5M | -$38.5M | -$46.8M | -$56.9M | -$11.5M | -$76.0M | -$72.4M | -$48.8M | -$48.0M | -$58.2M | $31.1M | -$49.3M |
| Net margin | −391.6% | −265.0% | −401.5% | −586.6% | −18.0% | −436.6% | −489.2% | −572.6% | −186.8% | −447.5% | 27.3% | −291.2% |
| Diluted EPS | $-2.33 | $-2.94 | — | $-6.70 | $-1.35 | $-9.08 | $-8.77 | $-5.90 | $-5.90 | $-9.50 | $5.09 | $-8.10 |
| EBITDA | -$28.4M | -$28.3M | -$32.0M | -$37.0M | $17.0M | -$45.6M | -$63.4M | -$66.1M | -$46.9M | -$54.8M | $44.9M | -$42.3M |
| Operating cash flow | -$38.3M | -$42.3M | -$26.4M | -$38.2M | -$44.7M | -$67.9M | -$71.7M | -$64.5M | $9.5M | -$64.7M | $14.1M | -$33.5M |
| Free cash flow | -$38.3M | -$42.3M | -$26.6M | -$38.4M | -$44.8M | -$69.1M | -$72.8M | -$65.3M | $8.7M | -$65.2M | $12.6M | -$33.8M |
| Diluted shares | 16.6M | 13.1M | — | 8.5M | 8.5M | 8.4M | 8.3M | 8.2M | 8.1M | 6.1M | 6.1M | 6.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $54.3M | $73.7M | $58.1M | $65.9M | $64.0M | $106.2M |
| Short-term investments | $110.0M | $128.9M | $83.3M | $101.7M | $141.1M | $142.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $194.5M | $242.0M | $173.8M | $209.7M | $262.4M | $321.4M |
| Total liabilities | $297.8M | $308.9M | $306.3M | $296.9M | $294.5M | $347.2M |
| Shareholders' equity | -$103.3M | -$66.9M | -$132.5M | -$87.3M | -$32.1M | -$25.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology